Context
A recent global phase 3 trial (SOUL trial) showed that oral semaglutide — a drug for type 2 diabetes — reduced the risk of heart attacks, strokes, and cardiovascular deaths by 14%, highlighting the need for cardio-renal protection in diabetes management.
Fact Box: About Diabetes
|
More Articles
Verifying, please be patient.